| Literature DB >> 33665077 |
Daniel Knox1,2, Kyle Halligan2.
Abstract
Percutaneous interventional tissue sampling of pulmonary masses and lymphadenopathy is a means for diagnosis of thoracic malignancy. The user base that can perform this skill with ultrasound guidance is expanding. A retrospective cohort of fine needle aspiration and percutaneous core biopsies was identified to evaluate their safety and efficacy. 47 distinct procedures were performed by a university medical center's Interventional Pulmonary service between 2012 and 2018.39 consecutive procedures were diagnostically successful by percutaneous means, with 34 of the successful diagnoses based on fine needle aspiration alone. In our cohort by percutaneous biopsy the most common diagnosis was Non-Small Cell Lung Cancer with 28 samples, followed by Small Cell Lung Cancer with 7 samples as well as additional solitary diagnoses of suspected infection, Hepatocellular Cancer, Hodgkin Lymphoma and Malignant Melanoma. 4 procedures had complications, two of which resolved post procedure with observation and two pneumothoracies which resolved with chest tube placement and hospital observation. A wide variety of diagnoses were obtained with percutaneous biopsies with 83% of percutaneous biopsies performed by Interventional Pulmonologists achieving diagnostic success.Entities:
Keywords: Lung cancer; Percutaneous lung biopsy; Procedure
Year: 2021 PMID: 33665077 PMCID: PMC7897983 DOI: 10.1016/j.rmcr.2021.101362
Source DB: PubMed Journal: Respir Med Case Rep ISSN: 2213-0071
Demographics mean (IQR) or % (n).
| Female | 60% (28) |
| Age | 68 (60,77) |
| BMI | 26 (22,30) |
| Height (cm) | 165 (157,171) |
| Weight (kg) | 70.3 (57.9,81.5) |
| Tobacco Use | |
| Never | 6% (3) |
| Active | 17% (12) |
| Quit | 51% (24) |
| No Data | 17% (8) |
Biopsy pathology vs. Final Pathology for all biopsy sites.
| Final Pathology | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Hepatocellular CA | Hodgkin lymphoma | Malignant melanoma | Non-diagnostic | Non-Small Cell Lung Cancer (NSCLC) | NSCLC: Adenocarcinoma | NSCLC: Squamous | Small Cell Lung Cancer | t-cell lymphoma | Infection likely | ||
| Biopsy Pathology | Infection Likely | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Hepatocellular CA | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Hodgkin lymphoma | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Malignant melanoma | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Non-diagnostic | 0 | 0 | 0 | 1 | 1 | 3 | 0 | 0 | 1 | 2 | |
| Non-Small Cell Lung Cancer (NSCLC) | 0 | 0 | 0 | 0 | 8 | 1 | 0 | 0 | 0 | 0 | |
| NSCLC: Adenocarcinoma | 0 | 0 | 0 | 0 | 0 | 11 | 0 | 0 | 0 | 0 | |
| NSCLC: Squamous | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 0 | 0 | 0 | |
| Small Cell Lung Cancer | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 0 | 0 | |
Final Pathology by size of tumor (in cm) for chest biopsies.
| 2 ≤ T < 4 | 4 ≤ T < 6 | 6 ≤ T < 8 | 8 ≤ T < 10 | 10 ≤ T | |
|---|---|---|---|---|---|
| Infection Likely | 1 | 0 | 0 | 0 | 0 |
| Hepatocellular CA | 0 | 1 | 0 | 0 | 0 |
| Hodgkin lymphoma | 0 | 0 | 1 | 0 | 0 |
| Malignant melanoma | 1 | 0 | 0 | 0 | 0 |
| Non-diagnostic | 2 | 1 | 3 | 0 | 0 |
| NSCLC | 1 | 2 | 1 | 0 | 1 |
| NSCLC: adenocarcinoma | 2 | 1 | 1 | 1 | 2 |
| NSCLC: squamous | 0 | 5 | 2 | 0 | 1 |
| Small cell | 1 | 0 | 1 | 0 | 1 |
Biopsy site data. N or mean (IQR).
| Transthoracic biopsies | Lymph node biopsies | |
|---|---|---|
| Number of procedures | 33 | 14 |
| Number of passes | 5 (3–7) | 5 (4–5) |
| Smaller Dimension (cm) | 5.6 (4–7) | 2 (2–2) |
| Larger Dimension (cm) | 7.6 (5–11) | 2 (2–2) |